The bottom line with AMBS is that at the current share price that anyone who is aware of the company's tremendous potential and isn't buying a few shares to hold for a year or two is missing a great opportunity to make substantial profits.
That's just the way it is.
AMBS is under strong accumulation. The total short volume for the week was in the 45% range.
New and existing shareholders are pulling shares out of the float for a long term hold. The up trend in the share price will continue and I expect one p.r. will double the share price in a day and AMBS will be on its way to up listing to the NASDAQ before the end of the second quarter of 2014.
The J.P. Morgan Healthcare Conference and the T.B.I. presentation at the United Nations are just two of the catalysts that will result in additional exposure of the company to the media and to new shareholders. The penny flippers and the shorts will be chasing the share price going forward.
Follow the company on Twitter: @AmarantusBio
Zack's analyst, Jason Napadano, put a "BUY" rating on AMBS with a .20 price target. Read his articles at SeekingAlpha.
Currently trading under a nickle.
Follow the company on Twitter: @AmarantusBio .... 8,639 followers.